Biofil Chemicals & Pharmaceuticals peers

Companies like Biofil Chemicals & Pharmaceuticalslatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

BIOFILCHEM₹29.26

Biofil Chemicals & Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersMANGALAMVINEETLABLASAORTINGLOBEKREBSBIOALPABALPHARMANATCAPSUQMcap ₹47.6 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
BIOFILCHEM
FY26
MANGALAM
FY26
VINEETLAB
FY26
LASA
FY26
Peer
Average
Valuation — at last close
P/E◆ 17.11×—36.06×—36.06× -53%
P/B2.21×◆ 0.45×1.52×0.47×0.81× +172%
EV/EBITDA72.85×◆ -10.12×11.50×-1.14×0.08× +92347%
Market Cap₹47.6 Cr₹46.1 Cr₹69.3 Cr₹23.4 Cr₹46.2 Cr +3%
Growth
Revenue CAGR 3Y◆ -1.85%—-34.59%-42.11%-38.35% +95%
Revenue CAGR 5Y◆ -4.50%—-24.58%-34.11%-29.34% +85%
Net Income CAGR 3Y◆ 70.67%—8.59%—8.59% +723%
Revenue YoY (latest Q)◆ 91.99%-0.40%39.66%-93.87%-18.20% +605%
Net Income YoY (latest Q)-95.47%44.64%◆ 274.84%83.05%134.18% -171%
Profitability
EBITDA Margin2.29%-6.42%◆ 14.27%-112.98%-35.04% +107%
Net Income Margin◆ 9.81%-19.13%2.70%-135.60%-50.68% +119%
Return on Common Equity◆ 13.81%-35.23%5.32%-51.13%-27.01% +151%
Return on Capital Employed1.83%-22.60%◆ 15.62%-51.42%-19.47% +109%
Return on Assets◆ 5.94%-13.03%1.46%-40.63%-17.40% +134%
Credit & Quality
Total Debt/Equity◆ 0.14×1.02×0.99×0.20×0.74× -81%
Interest Coverage◆ 37.37×-2.04×1.24×-89.13×-29.98× +225%
Scale — latest FY
Revenue / Total Income₹28.4 Cr₹232 Cr₹59.4 Cr₹25.1 Cr₹106 Cr -73%
Net Income₹2.8 Cr−₹44.4 Cr₹1.6 Cr−₹34.1 Cr−₹25.6 Cr +111%
Total Assets₹42.8 Cr₹315 Cr₹125 Cr₹66.3 Cr₹169 Cr -75%
EPS₹1.71₹-28.05₹1₹-6.8₹-11.28 +115%
Book Value per Share₹13.25₹65.11₹23.74₹9.9₹32.92 -60%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.